AlphAIAlphAI — Financial news for AI agents
investor.lilly.comOCT 93 min read$LLY

New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) advance understanding of the interconnected immune and metabolic biology in adults with psoriasis and obesity | Eli Lilly and Company

Eli Lilly presented Phase 3b data from the TOGETHER-PsO study, showing that Taltz (ixekizumab) and Zepbound (tirzepatide) together led to broader biomarker changes in psoriasis and obesity patients compared to Taltz alone. The combination therapy showed greater reductions in inflammatory immune activity and improved psoriasis-specific markers by Week 12. The study involved 274 participants and evaluated the efficacy and safety of the combination treatment over 52 weeks.

Original reporting
investor.lilly.com
Published Oct 9, 2026, 10:45 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 9, 2026, 11:20 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$LLY
Bullish
high confidence
Mentioned
$LLY
Relevance
7/10
AlphAI data visualization · based on investor.lilly.com
Decision brief

The 30-second read

$LLYBullishMed
01

Why it matters

The disclosed biomarker and efficacy improvements represent a new data point that could influence analyst forecasts and investor positioning in Lilly.

02

Market read

First‑time release of positive Phase 3b data may drive short‑term upside for LLY and influence broader biotech sentiment.

03

What to watch

regulatory timelines and payer reimbursement decisions could moderate impact

Relevance 7/10Novelty 8/10Timing: today

Background

Eli Lilly presented exploratory Phase 3b biomarker data for its combined Taltz and Zepbound regimen at Fall Clinical 2026, highlighting enhanced immune and metabolic effects versus Taltz alone.

Company-level read

Ticker impact

$LLYBullishHigh confidence
Context

Phase 3b data on Taltz (ixekizumab) and Zepbound (tirzepatide) showing broader biomarker changes and superior efficacy were disclosed for the first time.

Expected impact

likely upward pressure as market prices in the new efficacy data

Evidence & confidence

First‑time disclosure of significant biomarker improvements and superior clinical outcomes is material for a large‑cap biotech.

Market effects

Sector

could boost confidence in IL‑17 and dual GIP/GLP‑1 therapeutic approaches across biotech sector

Regional

U.S. biotech stocks may see modest gains

Global

global investors tracking obesity and psoriasis treatments may adjust exposure

Counterpoint

What could challenge this read

data may not translate into commercial success if safety or pricing issues emerge

Key entities

  • company
    Eli Lilly and Company

    US‑listed pharmaceutical company reporting Phase 3b trial data.

  • drug
    Taltz (ixekizumab)

    IL‑17A inhibitor for psoriasis and related indications.

  • drug
    Zepbound (tirzepatide)

    Dual GIP/GLP‑1 receptor agonist for obesity.

Read at source← All news

StoryEli Lilly presents exploratory biomarker data from TOGETHER‑PsO Phase 3b trial

Also covered by

2 outlets

Related articles

OCT 9
$LLYMedAI 9/10

New Weight-Loss Drug Helps People With Type 2 Diabetes Lose 21% of Their Body Weight

Eli Lilly's experimental drug, retatrutide, helped Type 2 diabetes patients lose 20.8% of their body weight in an 80-week trial. The highest dose group saw an average weight reduction of 49.6 pounds. The drug also improved blood sugar control, with 40% of participants on the two highest doses achieving normal blood sugar levels. The results were presented at the European Association for the Study of Diabetes meeting and published in The Lancet.

zmescience.com2 min
OCT 9
$LLYMedAI 8/10

Lilly Highlights Immune And Metabolic Effects Of Taltz Plus Zepbound

Eli Lilly reported Phase 3b data showing combined Taltz and Zepbound treatment led to broader changes in psoriasis-related, immune, and metabolic biomarkers compared to Taltz alone. The study involved adults with psoriasis and obesity or overweight. LLY closed at $1,169.60, down 1.61%, and is down 0.51% in pre-market trading.

rttnews.com2 min
OCT 9
$LLYMed

New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) advance understanding of the interconnected immune and metabolic biology in adults with psoriasis and obesity

Eli Lilly presented data from the TOGETHER-PsO Phase 3b trial showing that the combination of Taltz (ixekizumab) and Zepbound (tirzepatide) led to broader biomarker changes in psoriasis and metabolic markers compared to Taltz alone. The study involved 274 adults with psoriasis and obesity, with results presented at the 2026 Fall Clinical Dermatology Conference.

prnewswire.com2 min
OCT 8
$LLYHigh

Hand and Foot Eczema Responds Well to Lebrikizumab

A phase 3b trial of lebrikizumab (Ebglyss) showed over 50% of patients with moderate-to-severe hand and foot eczema achieved clear or almost clear skin. Significant reductions in itch and pain were reported, with 76.7% of patients satisfied with skin clearance. Lebrikizumab, approved for atopic dermatitis, is developed by Eli Lilly and Almirall in Europe.

medscape.com2 min
OCT 8
$LLYMed

Cantor Fitzgerald raises Eli Lilly stock price target on demand trends

Cantor Fitzgerald raised its price target for Eli Lilly (NYSE:LLY) to $1,440, citing strong demand trends and potential tailwinds from new products. The stock trades at $1,189 with a market cap of $1.06 trillion. Analysts note pricing headwinds but highlight a PEG ratio of 0.42 and 49.6% revenue growth. Recent FDA approvals and positive analyst ratings also support the stock.

investing.com2 min